Efficacy of Zemedy, a Mobile Digital Therapeutic for the Self-management of Irritable Bowel Syndrome: Crossover Randomized Controlled Trial

Melissa Hunt, Sofia Miguez, Benji Dukas, Obinna Onwude, Sarah White, Melissa Hunt, Sofia Miguez, Benji Dukas, Obinna Onwude, Sarah White

Abstract

Background: Patients with irritable bowel syndrome (IBS) experience abdominal pain, altered bowel habits, and defecation-related anxiety, which can result in reduced productivity and impaired health-related quality of life (HRQL). Cognitive behavioral therapy (CBT) has been shown to reduce symptoms of IBS and to improve HRQL, but access to qualified therapists is limited. Smartphone-based digital therapeutic interventions have potential to increase access to guided CBT at scale, but require careful study to assess their benefits and risks.

Objective: The aim of this study was to test the efficacy of a novel app, Zemedy, as a mobile digital therapeutic that delivers a comprehensive CBT program to individuals with IBS.

Methods: This was a crossover randomized controlled trial. Participants were recruited online and randomly allocated to either immediate treatment (n=62) or waitlist control (n=59) groups. The Zemedy app consists of 8 modules focusing on psychoeducation, relaxation training, exercise, the cognitive model of stress management, applying CBT to IBS symptoms, reducing avoidance through exposure therapy, behavioral experiments, and information about diet. Users interact with a chatbot that presents the information and encourages specific plans, homework, and exercises. The treatment was fully automated, with no therapist involvement or communication. At baseline and after 8 weeks, participants were asked to complete the battery of primary (Irritable Bowel Syndrome Quality of Life [IBS-QOL], Gastrointestinal Symptom Rating Scale [GSRS]) and secondary (Fear of Food Questionnaire [FFQ], Visceral Sensitivity Index [VSI], Gastrointestinal Cognition Questionnaire [GI-COG], Depression Anxiety Stress Scale [DASS], and Patient Health Questionnaire-9 [PHQ-9]) outcome measures. Waitlist controls were then offered the opportunity to crossover to treatment. All participants were assessed once more at 3 months posttreatment.

Results: Both intention-to-treat and completer analyses at posttreatment revealed significant improvement for the immediate treatment group compared to the waitlist control group on both primary and secondary outcome measures. Gains were generally maintained at 3 months posttreatment. Scores on the GSRS, IBS-QoL, GI-COG, VSI, and FFQ all improved significantly more in the treatment group (F1,79=20.49, P<.001, Cohen d=1.01; F1,79=20.12, P<.001, d=1.25; F1,79=34.71, P<.001, d=1.47; F1,79=18.7, P<.001, d=1.07; and F1,79=12.13, P=.001, d=0.62, respectively). Depression improved significantly as measured by the PHQ-9 (F1,79=10.5, P=.002, d=1.07), and the DASS Depression (F1,79=6.03, P=.02, d=.83) and Stress (F1,79=4.47, P=.04, d=0.65) subscales in the completer analysis but not in the intention-to-treat analysis. The impact of treatment on HRQL was mediated by reductions in catastrophizing and visceral sensitivity.

Conclusions: Despite its relatively benign physical profile, IBS can be an extraordinarily debilitating condition. Zemedy is an effective modality to deliver CBT for individuals with IBS, and could increase accessibility of this evidence-based treatment.

Trial registration: ClinicalTrials.gov NCT04170686; https://www.clinicaltrials.gov/ct2/show/NCT04170686.

Keywords: CBT; IBS; app; cognitive behavioral therapy; digital health; efficacy; irritable bowel syndrome; mHealth; randomized controlled trial; self-management.

Conflict of interest statement

Conflicts of Interest: OO has a financial ownership stake in Bold Health, which developed and markets the Zemedy app. MH, SM, BD, and SW have no conflicts to declare.

©Melissa Hunt, Sofia Miguez, Benji Dukas, Obinna Onwude, Sarah White. Originally published in JMIR mHealth and uHealth (https://mhealth.jmir.org), 20.05.2021.

Figures

Figure 1
Figure 1
Screenshots of Zemedy.
Figure 2
Figure 2
CONSORT diagram of participant flow through the study.

References

    1. Black CJ, Yiannakou Y, Houghton LA, Ford AC. Epidemiological, clinical, and psychological characteristics of individuals with self-reported irritable bowel syndrome based on the Rome IV vs Rome III criteria. Clin Gastroenterol Hepatol. 2020 Feb;18(2):392–398. doi: 10.1016/j.cgh.2019.05.037.
    1. Yeh H, Chien W, Chung C, Hu J, Tzeng N. Risk of psychiatric disorders in irritable bowel syndrome-A nationwide, population-based, cohort study. Int J Clin Pract. 2018 Jul 19;72(7):e13212. doi: 10.1111/ijcp.13212.
    1. Hunt M. Cognitive-behavioral therapy for irritable bowel syndrome. In: Sobin W, editor. Using central neuromodulators and psychological therapies to manage patients with disorders of gut-brain interaction. Switzerland: Springer, Cham; 2019. pp. 95–141.
    1. Simrén M, Törnblom H, Palsson OS, Van Oudenhove L, Whitehead WE, Tack J. Cumulative effects of psychologic distress, visceral hypersensitivity, and abnormal transit on patient-reported outcomes in irritable bowel syndrome. Gastroenterology. 2019 Aug;157(2):391–402. doi: 10.1053/j.gastro.2019.04.019.
    1. Zhang Y, Qin G, Liu D, Wang Y, Yao S. Increased expression of brain-derived neurotrophic factor is correlated with visceral hypersensitivity in patients with diarrhea-predominant irritable bowel syndrome. World J Gastroenterol. 2019 Jan 14;25(2):269–281. doi: 10.3748/wjg.v25.i2.269.
    1. Labus JS, Mayer EA, Chang L, Bolus R, Naliboff BD. The central role of gastrointestinal-specific anxiety in irritable bowel syndrome: further validation of the visceral sensitivity index. Psychosom Med. 2007 Jan;69(1):89–98. doi: 10.1097/PSY.0b013e31802e2f24.
    1. Addante R, Naliboff B, Shih W, Presson AP, Tillisch K, Mayer EA, Chang L. Predictors of health-related quality of life in irritable bowel syndrome patients compared with healthy individuals. J Clin Gastroenterol. 2019 Apr;53(4):e142–e149. doi: 10.1097/MCG.0000000000000978.
    1. Sherwin L, Leary E, Henderson WA. The association of catastrophizing with quality-of-life outcomes in patients with irritable bowel syndrome. Qual Life Res. 2017 Aug;26(8):2161–2170. doi: 10.1007/s11136-017-1554-0.
    1. Sugaya N, Kaiya H, Kumano H, Nomura S. Relationship between subtypes of irritable bowel syndrome and severity of symptoms associated with panic disorder. Scand J Gastroenterol. 2008;43(6):675–681. doi: 10.1080/00365520701883478.
    1. Kinsinger S. Cognitive-behavioral therapy for patients with irritable bowel syndrome: current insights. Psychol Res Behav Manag. 2017;10:231–237. doi: 10.2147/PRBM.S120817.
    1. Radziwon CD, Lackner JM. Cognitive behavioral therapy for IBS: how useful, how often, and how does it work? Curr Gastroenterol Rep. 2017 Aug 17;19(10):49–49. doi: 10.1007/s11894-017-0590-9.
    1. Henrich JF, Gjelsvik B, Surawy C, Evans E, Martin M. A randomized clinical trial of mindfulness-based cognitive therapy for women with irritable bowel syndrome-Effects and mechanisms. J Consult Clin Psychol. 2020 Apr;88(4):295–310. doi: 10.1037/ccp0000483.
    1. Laird K, Tanner-Smith E, Russell A, Hollon S, Walker L. Short-term and long-term efficacy of psychological therapies for irritable bowel syndrome: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016 Jul;14(7):937–947. doi: 10.1016/j.cgh.2015.11.020.
    1. Shah K, Ramos-Garcia M, Bhavsar J, Lehrer P. Mind-body treatments of irritable bowel syndrome symptoms: An updated meta-analysis. Behav Res Ther. 2020 May;128:103462. doi: 10.1016/j.brat.2019.103462.
    1. Hunt MG, Moshier S, Milonova M. Brief cognitive-behavioral internet therapy for irritable bowel syndrome. Behav Res Ther. 2009 Sep;47(9):797–802. doi: 10.1016/j.brat.2009.05.002.
    1. Craske MG, Wolitzky-Taylor KB, Labus J, Wu S, Frese M, Mayer EA, Naliboff BD. A cognitive-behavioral treatment for irritable bowel syndrome using interoceptive exposure to visceral sensations. Behav Res Ther. 2011 Jun;49(6-7):413–21. doi: 10.1016/j.brat.2011.04.001.
    1. Windgassen S, Moss-Morris R, Chilcot J, Sibelli A, Goldsmith K, Chalder T. The journey between brain and gut: A systematic review of psychological mechanisms of treatment effect in irritable bowel syndrome. Br J Health Psychol. 2017 Nov 01;22(4):701–736. doi: 10.1111/bjhp.12250.
    1. Inadomi J, Fennerty MB, Bjorkman D. Systematic review: the economic impact of irritable bowel syndrome. Aliment Pharmacol Ther. 2003 Oct 01;18(7):671–682. doi: 10.1046/j.1365-2036.2003.t01-1-01736.x.
    1. Ljótsson B, Hesser H, Andersson E, Lackner JM, El Alaoui S, Falk L, Aspvall K, Fransson J, Hammarlund K, Löfström A, Nowinski S, Lindfors P, Hedman E. Provoking symptoms to relieve symptoms: a randomized controlled dismantling study of exposure therapy in irritable bowel syndrome. Behav Res Ther. 2014 Apr;55:27–39. doi: 10.1016/j.brat.2014.01.007.
    1. Everitt HA, Landau S, O'Reilly G, Sibelli A, Hughes S, Windgassen S, Holland R, Little P, McCrone P, Bishop F, Goldsmith K, Coleman N, Logan R, Chalder T, Moss-Morris R, ACTIB trial group Assessing telephone-delivered cognitive-behavioural therapy (CBT) and web-delivered CBT versus treatment as usual in irritable bowel syndrome (ACTIB): a multicentre randomised trial. Gut. 2019 Sep;68(9):1613–1623. doi: 10.1136/gutjnl-2018-317805.
    1. Hunt M. Reclaim your life from IBS: A scientifically proven plan for relief without restrictive diets. New York: Sterling; 2016. Apr 05,
    1. Hunt MG, Ertel E, Coello JA, Rodriguez L. Empirical support for a self-help treatment for IBS. Cogn Ther Res. 2014 Oct 19;39(2):215–227. doi: 10.1007/s10608-014-9647-3.
    1. Sumant O. mHealth Market Size, Share and Trends: Industry Growth, 2027. Allied Market Research. 2020. [2020-04-20]. .
    1. Rathbone AL, Clarry L, Prescott J. Assessing the efficacy of mobile health apps using the basic principles of cognitive behavioral therapy: systematic review. J Med Internet Res. 2017 Nov 28;19(11):e399. doi: 10.2196/jmir.8598.
    1. Gardiner PM, McCue KD, Negash LM, Cheng T, White LF, Yinusa-Nyahkoon L, Jack BW, Bickmore TW. Engaging women with an embodied conversational agent to deliver mindfulness and lifestyle recommendations: A feasibility randomized control trial. Patient Educ Couns. 2017 Sep;100(9):1720–1729. doi: 10.1016/j.pec.2017.04.015.
    1. Haug S, Schaub MP, Venzin V, Meyer C, John U, Gmel G. A pre-post study on the appropriateness and effectiveness of a Web- and text messaging-based intervention to reduce problem drinking in emerging adults. J Med Internet Res. 2013 Sep 02;15(9):e196. doi: 10.2196/jmir.2755.
    1. Kelders SM, Bohlmeijer ET, Pots WTM, van Gemert-Pijnen JEWC. Comparing human and automated support for depression: Fractional factorial randomized controlled trial. Behav Res Ther. 2015 Sep;72:72–80. doi: 10.1016/j.brat.2015.06.014.
    1. Mason EC, Andrews G. The use of automated assessments in internet-based CBT: The computer will be with you shortly. Internet Interv. 2014 Oct;1(4):216–224. doi: 10.1016/j.invent.2014.10.003.
    1. Hauser-Ulrich S, Künzli H, Meier-Peterhans D, Kowatsch T. A smartphone-based health care chatbot to promote self-management of chronic pain (SELMA): pilot randomized controlled trial. JMIR Mhealth Uhealth. 2020 Apr 03;8(4):e15806. doi: 10.2196/15806.
    1. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H, Corbett MS, Eldridge SM, Emberson JR, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019 Aug 28;366:l4898. doi: 10.1136/bmj.l4898.
    1. Drossman DA, Patrick DL, Whitehead WE, Toner BB, Diamant NE, Hu Y, Jia H, Bangdiwala SI. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol. 2000 Apr;95(4):999–1007. doi: 10.1111/j.1572-0241.2000.01941.x.
    1. Patrick DL, Drossman DA, Frederick IO, DiCesare J, Puder KL. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci. 1998 Feb;43(2):400–411. doi: 10.1023/a:1018831127942.
    1. Wiklund IK, Fullerton S, Hawkey CJ, Jones RH, Longstreth GF, Mayer EA, Peacock RA, Wilson IK, Naesdal J. An irritable bowel syndrome-specific symptom questionnaire: development and validation. Scand J Gastroenterol. 2003 Sep;38(9):947–954. doi: 10.1080/00365520310004209.
    1. Drossman DA, Chang L, Bellamy N, Gallo-Torres HE, Lembo A, Mearin F, Norton NJ, Whorwell P. Severity in irritable bowel syndrome: a Rome Foundation Working Team report. Am J Gastroenterol. 2011 Oct;106(10):1749–59; quiz 1760. doi: 10.1038/ajg.2011.201.
    1. Palsson OS, van Tilburg MA, Simren M, Sperber AD, Whitehead WE. Mo1642 Population prevalence of Rome IV and Rome III irritable bowel syndrome (IBS) in the United States (US), Canada and the United Kingdom (UK) Gastroenterology. 2016 Apr;150(4):S739–S740. doi: 10.1016/s0016-5085(16)32513-6.
    1. Hunt M, Zickgraf H, Gibbons B, Loftus P. Development and validation of the Fear of Food Questionnaire (FFQ). Annual Meeting of the Anxiety and Depression Association of America; April 19, 2018; Washington, DC. 2018.
    1. Labus J, Bolus R, Chang L, Wiklund I, Naesdal J, Mayer EA, Naliboff BD. The Visceral Sensitivity Index: development and validation of a gastrointestinal symptom-specific anxiety scale. Aliment Pharmacol Ther. 2004 Jul 01;20(1):89–97. doi: 10.1111/j.1365-2036.2004.02007.x.
    1. Hazlett-Stevens H, Craske MG, Mayer EA, Chang L, Naliboff BD. Prevalence of irritable bowel syndrome among university students. J Psychosom Res. 2003 Dec;55(6):501–505. doi: 10.1016/s0022-3999(03)00019-9.
    1. Hunt M, Ertel E, Coello JA, Rodriguez L. Development and validation of the GI-Cognitions Questionnaire. Cogn Ther Res. 2014 Mar 4;38(4):472–482. doi: 10.1007/s10608-014-9607-y.
    1. Brown TA, Chorpita BF, Korotitsch W, Barlow DH. Psychometric properties of the Depression Anxiety Stress Scales (DASS) in clinical samples. Behav Res Ther. 1997 Jan;35(1):79–89. doi: 10.1016/s0005-7967(96)00068-x.
    1. Parkitny L, McAuley J. The Depression Anxiety Stress Scale (DASS) J Physiother. 2010;56(3):204. doi: 10.1016/s1836-9553(10)70030-8.
    1. Crawford JR, Henry JD. The Depression Anxiety Stress Scales (DASS): normative data and latent structure in a large non-clinical sample. Br J Clin Psychol. 2003 Jun;42(Pt 2):111–131. doi: 10.1348/014466503321903544.
    1. Kroenke K, Spitzer RL, Williams JBW. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606–613. doi: 10.1046/j.1525-1497.2001.016009606.x.
    1. Nevalainen J, Kenward MG, Virtanen SM. Missing values in longitudinal dietary data: a multiple imputation approach based on a fully conditional specification. Stat Med. 2009 Dec 20;28(29):3657–3669. doi: 10.1002/sim.3731.
    1. Hayes AF. Introduction to mediation, moderation, and conditional process analysis: a regression-based approach, Second edition. New York: Guilford Press; 2017. Dec 13,
    1. Jacobson NS, Truax P. Clinical significance: A statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol. 1991;59(1):12–19. doi: 10.1037/0022-006x.59.1.12.
    1. Patel SM, Stason WB, Legedza A, Ock SM, Kaptchuk TJ, Conboy L, Canenguez K, Park JK, Kelly E, Jacobson E, Kerr CE, Lembo AJ. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil. 2005 Jun;17(3):332–340. doi: 10.1111/j.1365-2982.2005.00650.x.
    1. Mathieu E, McGeechan K, Barratt A, Herbert R. Internet-based randomized controlled trials: a systematic review. J Am Med Inform Assoc. 2013 May 01;20(3):568–576. doi: 10.1136/amiajnl-2012-001175.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir